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background:  Mechanical circulatory support (MCS) devices - namely the intra-aortic balloon pump (IABP) and the percutaneous 
ventricular assist devices (PVAD) are widely used for supporting percutaneous coronary intervention (PCI) in high-risk patients. Given 
the paucity of data from randomized controlled trials, we examined differences in patient characteristics and clinical outcomes in patients 
undergoing PCI with the use of IABP and PVAD.
methods:  We used the National Inpatient Sample 2007-2012 data to identify all adult patients (> 18 years) who underwent placement of 
a PVAD (ICD-9 code 37.68) or IABP (ICD-9 code 37.61) on the same day as PCI during 2007-2012. We compared the risk of in-hospital 
mortality with the use of IABP vs. PVAD using a survey-specific logistic regression model. Sensitivity analysis compared IABP and PVAD in 
patients undergoing PCI without cardiogenic shock.
results:  During 2007-2012, IABP was used on the same day as PCI in 89,579 patients, while PVADs were used in 4950 patients. 
Compared to IABP, PVAD patients were older (64.6 vs. 69.0 years), more likely to be men (69.6% vs. 74.2%) but less likely to have acute 
myocardial infarction (AMI: 90.9% vs. 52.4%), cardiogenic shock (52.2% vs. 26.1%) or cardiac arrest (26.4% vs. 12.2%; P<0.01 for all). In 
contrast, prevalence of heart failure (42.9% vs. 68.9%), chronic kidney disease (13.6% vs. 27.6%), hypertension (59.1% vs. 70.7%) and 
diabetes (35.0% vs. 46.8%) was higher in PVAD patients (p<0.01 for all). In-hospital mortality was significant lower in the PVAD group 
compared to IABP (13.0% vs. 21.1%) even after adjustment of patient factors (odds ratio [OR] 0.72 [95% CI 0.57 - 0.90] p<0.01). However, 
the difference in mortality was no longer significant after adjustment for cardiogenic shock (OR for PVAD vs. IABP: 0.85 [95% CI 0.67-
1.07]). In patients without cardiogenic shock, use of PVAD was associated with significantly lower mortality (adjusted OR 0.53 [95% C.I. 
0.36 - 0.78]).
Conclusion:  In patients undergoing PCI with MCS, PVADs were associated with lower mortality compared to IABP, especially in patients 
without cardiogenic shock. These findings need to be confirmed in a prospective randomized controlled trial.
